MiniMed Group, Inc. has announced CE Mark approval for use of the MiniMed 780G system with the Instinct sensor, made by Abbott. This further expands sensor choice for users of its most advanced automated insulin delivery system says the company.
“At MiniMed, every advancement begins with listening to the needs of people living with diabetes,” said Que Dallara, CEO of MiniMed. “By offering more sensor flexibility within a fully integrated system — backed by the proven clinical outcomes of our MiniMed™ 780G system — we’re helping lighten the burden of daily management and giving individuals the freedom to choose what works best for them.”
The MiniMed 780G system is already compatible with the Guardian 4 and Simplera Sync sensors, which both offer up to seven days of wear. The Instinct sensor, designed exclusively by Abbott for MiniMed automated insulin delivery (AID) is the world’s smallest, thinnest, most discreet CGM claims MiniMed and offers a wear time of up to 15 days. MiniMed 780G system users can now choose between a 7-day or 15-day sensor.
MiniMed says it anticipates the commercial launch of the MiniMed 780G system with Instinct sensor in the first European countries during the summer. The company will be presenting the full system at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) taking place in Barcelona from March 11-14, 2026.
In Europe the MiniMed 780G system is indicated for use by individuals aged 2 years and older with insulin-requiring diabetes (type 1 and type 2), whose total daily dose of insulin is 6 units per day or more. The system is also CE Marked in Europe for use during pregnancy.
In the U.S., the MiniMed 780G system is indicated for use by individuals with type 1 diabetes aged 7 years and older, and for insulin-requiring type 2 diabetes aged 18 years and older with clinical trials underway to examine the use of the MiniMed 780G system in 2–6-year-olds. The MiniMed 780G system has not been approved for use in pregnancy by the FDA.
